Although the traditional approach to identifying cancer-causing genetic alterations and interactions has been focused on single genes or proteins, we increasingly recognize that alterations of biological processes involve coordinated changes in the expression of dozens or hundreds of genes, or in the activity of multiple signaling pathways. With the availability of the complete sequence of the human and mouse genomes, experimentalists can now use global approaches that simultaneously examine multitudes of genes at once. In addition, the ability to collect these rich data from clinical specimens using automated analysis of images, or proteomic approaches to the kinome, is also rapidly growing. These developments necessitate the integration of genetics, genomics and proteomics, with pathology and clinical oncology research. To manage and analyze these complex datasets, translational researchers must be facile with bioinformatics, statistics, and biostatistics. In response to these needs, the UNC Breast SPORE has developed Core B, the Genomics, Biostatistics, and Bioinformatics shared resource. Under the experienced leadership of the SPORE Co-PI Charles Perou (Genetics), Dr. Joe Ibrahim (Biostatistics) and Dr. Steve Marron (Statistics), Core B brings together under one roof three critical services - Genomic assays (DNA microarrays, mRNA- sequencing and gene expression profiling using FFPE RNA and the Nanostring platform), a robust Bioinformatics computing environment, and expertise in Biostatistics and Statistics - and focuses these resources on translational breast cancer research. All proposed SPORE Projects (1-5) will work with Core B. The Core B services are tunneled into this core through three UNC Lineberger Comprehensive Cancer Center (LCCC) shared resources - namely the Genomics Core Facility, the Bioinformatics Core, and the Biostatistics Core. In all of these LCCC Cores, the studies of Breast SPORE investigators have spurred the development of methods and equipment upgrades that have benefited and stimulated other Cancer Center research. By supporting key personnel in these LCCC Cores, the UNC Breast SPORE is assuring priority service and performance. Dr. Perou's expertise and experience with these services, and his leadership of the Cancer Center's Genomics &Bioinformatics Cores, together with Dr. Marron and Dr. Ibrahim's experience as the LCCC Biostatistics Core leader, means that Core B is integral to this Breast SPORE, integrated into the Cancer Center structure, and poised to provide priority services for Breast SPORE investigators.

Public Health Relevance

Cancer biology and clinical medicine are becoming more and more dependent upon the analysis of complex and large datasets, which are often based upon genomic and/or proteomic data accompanied by pathological and clinical data. The coordinated analysis of these multiple data types requires a highly sophisticated, facile, and rigorous bioinformatics and statistical infrastructure. This Core brings together all the needed expertise and tools for these computational challenges so that advances in breast cancer treatment can be made.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Mobley, Robert J; Raghu, Deepthi; Duke, Lauren D et al. (2017) MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. Cell Rep 18:2387-2400
Kohler, Racquel E; Gopal, Satish; Miller, Anna R et al. (2017) A framework for improving early detection of breast cancer in sub-Saharan Africa: A qualitative study of help-seeking behaviors among Malawian women. Patient Educ Couns 100:167-173
Valle, Carmina G; Deal, Allison M; Tate, Deborah F (2017) Preventing weight gain in African American breast cancer survivors using smart scales and activity trackers: a randomized controlled pilot study. J Cancer Surviv 11:133-148
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, Jose Angel et al. (2017) Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clin Cancer Res 23:649-657
Mullooly, Maeve; Yang, Hannah P; Falk, Roni T et al. (2017) Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Res 19:8
Hoffman, Joshua D; Graff, Rebecca E; Emami, Nima C et al. (2017) Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk. PLoS Genet 13:e1006690
Visvanathan, Kala; Fackler, MaryJo S; Zhang, Zhe et al. (2017) Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. J Clin Oncol 35:751-758
Zawistowski, Jon S; Bevill, Samantha M; Goulet, Daniel R et al. (2017) Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov 7:302-321
Bowerman, Charles J; Byrne, James D; Chu, Kevin S et al. (2017) Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett 17:242-248
Heng, Yujing J; Lester, Susan C; Tse, Gary Mk et al. (2017) The molecular basis of breast cancer pathological phenotypes. J Pathol 241:375-391

Showing the most recent 10 out of 548 publications